Chiesi Group’s agreement to acquire KalVista Pharmaceuticals for about $1.9 billion is more than a niche biotech takeover. It is a useful read on what strategic buyers are still willing to pay for in a tougher market: not early-stage promise, but a recently approved drug with visible commercial traction and room to expand globally.
Under the agreement announced on April 29, the privately held Italian drugmaker will pay $27 a share in cash for KalVista through a tender offer, with the transaction expected to close in the third quarter of 2026 if customary conditions are met. The companies said the offer represents a 36% premium to KalVista’s 30-day volume-weighted average share price as of April 28, and Chiesi said the deal is not subject to any financing condition. That matters because it signals conviction from a buyer that is using a balance-sheet-backed bid to secure an asset it views as strategically important rather than opportunistic.
What Chiesi is buying is not just a pipeline. It is EKTERLY, known generically as sebetralstat, which KalVista developed as the first and only oral, on-demand treatment for hereditary angioedema attacks. The U.S. Food and Drug Administration approved the drug on July 3, 2025 for adults and pediatric patients 12 years and older, giving patients an alternative to injected rescue therapies in a disease where speed, convenience and reliability matter. KalVista launched the product in the United States on July 7, 2025 and reported $49.1 million in global net product revenue for the eight months ended December 31, 2025. By the end of February, the company said it had received 1,702 U.S. patient start forms.
Those figures are still small by large-pharma standards, but they are large enough to answer the most expensive question in rare-disease investing: whether patients and prescribers will actually switch once a scientifically promising drug reaches the market. Too many biotech stories stall at exactly that point. KalVista had already crossed it. For Chiesi, that reduces one layer of risk and turns the acquisition into a commercial scaling exercise rather than a pure development bet.
The strategic logic is also straightforward. Chiesi said EKTERLY will strengthen its rare immunology portfolio, expand its commercial infrastructure and market presence in the United States, and contribute meaningfully to its 2030 revenue target of 6 billion euros. In other words, this is not a portfolio filler. It is an attempt to deepen Chiesi’s position in rare diseases with a product that already has regulatory validation in multiple markets and still has expansion potential, including ongoing work in children ages 2 to 11 and additional regulatory filings in key geographies.
That broader implication is what makes the deal worth watching beyond biotech specialists. Public markets have often treated smaller drug developers as if commercial success alone is not enough to rerate them for long. Chiesi’s bid suggests strategic buyers may see more value than public investors do when a company controls a differentiated therapy, owns the launch, and can still widen the addressable market. The premium also hints that scarce assets with real-world uptake can command better prices than companies that are still asking investors to underwrite years of clinical and launch uncertainty.
There is still execution risk. Tender offers need shareholder participation, regulatory clearance and clean integration, and hereditary angioedema is becoming more competitive as new treatment formats reach the market. But Chiesi appears to be making a deliberate calculation that convenience can be a durable advantage in rare disease, especially when it changes how patients use therapy during an acute attack rather than only how often they prevent one.
For KalVista shareholders, the deal delivers a cash exit at a substantial premium less than a year after EKTERLY reached the U.S. market. For Chiesi, it is a statement that one of the clearest ways to grow in specialty pharma is still to buy proven adoption early, before a successful launch fully compounds into a much larger valuation. In a market crowded with stories about cost cuts, capital discipline and risk aversion, that is a reminder that buyers will still move aggressively when a product has already begun to prove itself.